Recent updates to this opportunity clarify the research scope, specifically noting that biomarker studies should focus on preclinical or subclinical autoimmune disease rather than just early-stage disease. The guidelines also emphasize that any therapeutic strategies you propose must target mechanisms common to T1D, MS, and SLE. Rest assured, your anticipated January 2027 deadline and $150,000 funding limit remain unchanged.
Funder: Breakthrough T1D
Due Dates (Anticipated): January 2027 (Full proposal deadline, projected)
Funding Amounts: Up to $150,000 for one year (includes up to 10% indirect costs)
Summary: Funds one-year proof-of-concept research to uncover shared and unique immune pathways in autoimmune diseases, fostering cross-disciplinary collaboration.
Key Information: Proposals must address mechanisms relevant to at least two autoimmune diseases (T1D, MS, and/or SLE); no clinical trials or projects exceeding one year.